The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases. The inventors herein disclose a series of heterocyclic compounds that inhibit HIF pathway activity, promote VHL and PHD mediated degradation of HIF, and have improved oral bioavailability. The invention includes a method of treatment of a disease caused by abnormal cell proliferation comprising the administration of a therapeutically effective amount of a compound as disclosed herein to a patient in need thereof.La présente invention concerne des sels de composés hétérocycliques et des méthodes qui inhibent l'activité de la voie HIF. Les composés sont conçus pour traiter ou prévenir le cancer et d'autres maladies médiées par l'hypoxie.
